The significant cancer therapy potential of the combination of IL-12 and IL-15 promises to take advantage of IL-12’s ability to prime innate/adaptive immune responses, while IL-15 can boost and maintain an antitumor response (28, 29). This evidence concerns the gene IL15 and cancer.